Skadden is advising Otsuka, while Latham & Watkins is advising Jnana on the deal. Nutraceutical and pharmaceutical company Otsuka Holdings Co. Ltd., (Otsuka), announced the definitive...
Otsuka Pharmaceutical’s Acquisition of Jnana Therapeutics
Serenity Kids’ $52 Million Series B Funding Round
Haynes and Boone represented Serenity Kids in the transaction, and Latham & Watkins represented Stride Consumer Partners. Serenity Kids, a shelf-stable pouched baby food brand, announced...
Janux Therapeutics’ $296.5 Million Common Stock Offering
Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
AbbVie’s Acquisition of Cerevel Therapeutics
Kirkland & Ellis advised AbbVie, Latham & Watkins advised Cerevel Therapeutics, Skadden advised Centerview partners LLC, as financial advisor to Cerevel Therapeutics in the transaction. AbbVie...
WestView Capital Partners’ investment in Hubstaff
Latham & Watkins advises WestView Capital Partners in its investment in Hubstaff WestView Capital Partners made a strategic investment in Hubstaff as the workforce management software company capitalizes...
Performance Livestock Analytics’ Funding Round Led By Builders VC
Latham & Watkins advises Performance Livestock Analytics in funding and separation from Zoetis. Performance Livestock Analytics (PLA), an independent precision livestock platform using cattle data and...
Ikena Oncology’s Acquisition of Pionyr Immunotherapeutics
Latham & Watkins advised Pionyr on the sale. Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena) and Pionyr Immunotherapeutics, Inc. have announced the closing of Ikena’s acquisition of...
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
Francisco Partners and TPG’s $6.5 Billion Acquisition of New Relic
Davis Polk & Wardwell and Paul Hastings LLP are advising Francisco Partners and TPG, and Latham & Watkins LLP is advising New Relic on the transaction....
Cadence’s Acquisition of Rambus PHY IP Assets
Latham & Watkins advised Cadence, and Wilson Sonsini Goodrich & Rosati advised Rambus on the transaction. Cadence Design Systems, Inc. and Rambus Inc. announced that they have entered...
TA Associates Strategic Growth Investment in Alpha II
Latham & Watkins advises Alpha II and existing shareholder WestView Capital Partners on TA Associates strategic Growth investment. TA Associates, a leading global private equity firm,...
Guardant Health’s Upsized Public Offering of Common Stock
Latham & Watkins Advises Guardant Health in Pricing of Upsized Public Offering of Common Stock. Guardant Health, Inc., a leading precision oncology company, has announced the pricing...